Achillion Pharmaceuticals, Inc. (ACHN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.45+0.05 (+0.60%)
As of 10:42 AM EDT. Market open.
People also watch:
FOLDACADARIACLDXARRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open8.37
Prev Close8.40
Bid8.47 x 300
Ask8.48 x 800
Day's Range8.36 - 8.53
52wk Range5.57 - 10.95
1y Target EstN/A
Market Cap1.15B
P/E Ratio (ttm)172.45
Beta2.26
Volume176,388
Avg Vol (3m)1,331,159
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : August 29, 2016
    Capital Cubeyesterday

    Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : August 29, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Achillion Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Barrons.com13 days ago

    Gilead Sciences: Still Dominating Hepatitis C But…

    After surveying doctors on the preferred hepatitis-C treatments, Baird's Brian Skorney and Neena Bitritto-Garg contend that Gilead Sciences (GILD) is likely to maintain its dominance over AbbVie (ABBV), Merck (MRK) and Johnson & Johnson (JNJ) but in what appears to be a shrinking market. In conjunction with script trends, physicians indicate that the market for treatment-eligible, easily accessible Hep C patients is shrinking, but that Gilead's share of the shrinking pie is continuing to grow.

  • Is Achillion Pharmaceuticals (ACHN) Stock a Solid Choice Right Now?
    Zacks18 days ago

    Is Achillion Pharmaceuticals (ACHN) Stock a Solid Choice Right Now?

    Achillion Pharmaceuticals (ACHN) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.